Financials
Financial year 2025
ERS ENDOCRINOLOGIE from Bastogne, company number BE0824351233, closed financial year 2025 with a result of € 65,903 after tax. For that financial year ERS ENDOCRINOLOGIE recorded a gross margin of € 147,265 and equity of € 345,396. Compared with financial year 2024, the result moved from € 61,932 to € 65,903. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 4, 2026.
€ 345,396
▲ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 65,903
▲ 6% vs 2024
Profit after tax over the fiscal year.
€ 272,068
▲ 10% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 36,362 paid out
55 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 17,744
▼ 29% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 4,241
▼ 7% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 10,510
▲ 16% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 125,531 | € 122,754 | € 123,579 | € 147,265 | ▲ 19% |
| Profit after taxes | € 62,060 | € 48,152 | € 61,932 | € 65,903 | ▲ 6% |
| Equity | € 263,267 | € 281,056 | € 315,854 | € 345,396 | ▲ 9% |
| Total debts | € 20,532 | € 25,984 | € 30,313 | € 31,853 | ▲ 5% |
| Cash | € 169,761 | € 102,772 | € 248,231 | € 272,068 | ▲ 10% |
| Retained profit | € 244,667 | € 262,456 | € 297,254 | € 326,796 | ▲ 10% |
| Dividend | € 800 | € 30,363 | € 27,134 | € 36,362 | ▲ 34% |
| Balance sheet total | € 287,430 | € 310,670 | € 346,167 | € 377,249 | ▲ 9% |
Key figures of ERS ENDOCRINOLOGIE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ERS ENDOCRINOLOGIE?
What happened at ERS ENDOCRINOLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 65,903 (▲ 6% vs 2024). filed late Source: NBB ↗
- Vincent ERS became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 62,060 profit in 2022 to € 65,903 profit in 2025.
Paid € 90,518 in corporate taxes since 2022.
Best year ever: 2025, with € 65,903 profit.
Paid out € 94,659 in dividends to the owners in total.
Management
Behind ERS ENDOCRINOLOGIE is Vincent ERS. Vincent ERS is also behind FONDS DE PROMOTION MEDICAL DES CLINIQUES DU SUD LUXEMBOURG.
Directors
According to the 2025 annual accounts
since 2023
Establishments
Establishment units
Physical locations of this company
Rue Saint-Fiacre(Marvie) 69
6600 Bastogne
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0824.351.233
- VAT number
- BE 0824.351.233
- Registered office
- Rue Saint-Fiacre(Marvie) 69, 6600 Bastogne
- Names & denominations
- ERS ENDOCRINOLOGIE
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 March 2010
- Peppol
- Active · Active since 21 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering